An AI diagnostic tool that estimates cardiac age based on ECG data to present cardiovascular event risk as a risk indicator. It analyzes ECG signals to predict cardiovascular disease risk and supports clinical decision-making for patient management.
Manufactured by
South Korea
DeepCardio leverages AI-driven analysis of ECG (electrocardiogram) data to detect heart diseases. Founded in 2020, we have co-developed with leading medical centers. We received MFDS (Ministry of Food and Drug Safety) approval in 2024 for our AF (Atrial Fibrillation) AI-ECG solution. As we pursuing MFDS approval for solutions of CV (cardiovascular) risk and EF estimation, we are evloving into a cardiology-focused vertical AI company.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Rossmax Swiss GmbH
Switzerland · 1 relevant product
Harvey Cardio Co., Ltd.
South Korea · 1 relevant product
ARPI, Inc
South Korea · 4 relevant products
35 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →11 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 42 closest product alternatives
Rossmax Swiss GmbH · Switzerland
Diagnostic device capable of assessing early stroke risk through single blood pressure measurement. Provides rapid cardiovascular risk assessment for clinical decision-making.
Harvey Cardio Co., Ltd. · South Korea
Non-invasive pulse wave recording and analysis system for cardiovascular disease risk assessment. Generates clinical measurements including central systolic blood pressure, pulse wave velocity, and heart-brain relative risk scores through advanced tonometry sensors and AI algorithms.
ARPI, Inc · South Korea
An AI-powered electrocardiogram analysis solution for outpatient cardiac risk screening. The system analyzes five digital biomarkers including left ventricular ejection fraction, left ventricular hypertrophy, coronary arterial obstructive disease, paroxysmal atrial fibrillation, and hypertrophic cardiomyopathy to enable early detection and monitoring of chronic and latent cardiac conditions. It is approved as a Class III medical device by the Korean Ministry of Food and Drug Safety.
39 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products